Literature DB >> 17006605

Molecular analysis of two uncharacterized sequence variants of the VHL gene.

Maddalena Martella1, Leonardo Salviati2, Alberto Casarin1, Eva Trevisson1, Giuseppe Opocher3, Roberta Polli1, David Gross4, Alessandra Murgia5.   

Abstract

Mutations in the VHL gene cause von Hippel-Lindau disease, a cancer predisposing syndrome characterized by a variety of benign and malignant neoplasms. We report the molecular characterization of two sequence variants of the VHL gene: a synonymous substitution c.462 A>C in exon 2 and a duplication of 11 bp in the promoter region (c.-65_-55dup11). The first variant is a pathogenic mutation because, although it does not change the sense of the affected codon, it causes skipping of exon 2 in the affected allele by altering the splicing consensus site at the 3' end of exon 2. The 11 bp duplication represents a nonpathogenic variant. In fact, although it affects a critical region of the VHL promoter, it was found in healthy controls, and we show that carrier individuals express both VHL alleles at equimolar levels. Our data underline the importance of careful evaluation of the potential pathogenicity of sequence variants that may not belong to the obvious disease-causing mutation categories, or that affect relevant regulatory regions. mRNA analysis will be required to ultimately resolve this issue.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17006605     DOI: 10.1007/s10038-006-0054-9

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  12 in total

Review 1.  Listening to silence and understanding nonsense: exonic mutations that affect splicing.

Authors:  Luca Cartegni; Shern L Chew; Adrian R Krainer
Journal:  Nat Rev Genet       Date:  2002-04       Impact factor: 53.242

2.  Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.

Authors:  S Gläsker; B U Bender; T W Apel; V van Velthoven; L M Mulligan; J Zentner; H P Neumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

3.  Somatic mosaicism in von Hippel-Lindau Disease.

Authors:  A Murgia; M Martella; C Vinanzi; R Polli; G Perilongo; G Opocher
Journal:  Hum Mutat       Date:  2000-01       Impact factor: 4.878

4.  Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome.

Authors:  L B Møller; Z Tümer; C Lund; C Petersen; T Cole; R Hanusch; J Seidel; L R Jensen; N Horn
Journal:  Am J Hum Genet       Date:  2000-03-17       Impact factor: 11.025

5.  Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene.

Authors:  C Stolle; G Glenn; B Zbar; J S Humphrey; P Choyke; M Walther; S Pack; K Hurley; C Andrey; R Klausner; W M Linehan
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

Review 6.  The VHL tumour-suppressor gene paradigm.

Authors:  W G Kaelin; E R Maher
Journal:  Trends Genet       Date:  1998-10       Impact factor: 11.639

7.  Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma.

Authors:  S Olschwang; S Richard; C Boisson; S Giraud; P Laurent-Puig; F Resche; G Thomas
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

8.  Von Hippel-Lindau disease: a genetic study.

Authors:  E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

9.  Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.

Authors:  M Zatyka; C Morrissey; I Kuzmin; M I Lerman; F Latif; F M Richards; E R Maher
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

10.  Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene.

Authors:  I Kuzmin; F M Duh; F Latif; L Geil; B Zbar; M I Lerman
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

View more
  7 in total

1.  A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease.

Authors:  Shahida K Flores; Ziming Cheng; Angela M Jasper; Keiko Natori; Takahiro Okamoto; Akiyo Tanabe; Koro Gotoh; Hirotaka Shibata; Akihiro Sakurai; Takuya Nakai; Xiaojing Wang; Magnus Zethoven; Shiva Balachander; Yuichi Aita; William Young; Siyuan Zheng; Kazuhiro Takekoshi; Eijiro Nakamura; Richard W Tothill; Ricardo C T Aguiar; Patricia L M Dahia
Journal:  J Clin Endocrinol Metab       Date:  2019-04-04       Impact factor: 5.958

2.  An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma.

Authors:  Lucia Anna Muscarella; Raffaela Barbano; Bartolomeo Augello; Vincenza Formica; Lucia Micale; Leopoldo Zelante; Leonardo D'Agruma; Giuseppe Merla
Journal:  J Hum Genet       Date:  2007-04-17       Impact factor: 3.172

Review 3.  The functional relevance of somatic synonymous mutations in melanoma and other cancers.

Authors:  Valer Gotea; Jared J Gartner; Nouar Qutob; Laura Elnitski; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2015-11       Impact factor: 4.693

4.  Von Hippel-Lindau disease: an evaluation of natural history and functional disability.

Authors:  Alberto Feletti; Mariagiulia Anglani; Bruno Scarpa; Francesca Schiavi; Francesca Boaretto; Stefania Zovato; Elisa Taschin; Mario Gardi; Elisabetta Zanoletti; Stefano Piermarocchi; Alessandra Murgia; Giacomo Pavesi; Giuseppe Opocher
Journal:  Neuro Oncol       Date:  2016-01-12       Impact factor: 12.300

5.  Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma.

Authors:  Claire Taylor; Rachel A Craven; Patricia Harnden; Peter J Selby; Rosamonde E Banks
Journal:  Int J Oncol       Date:  2012-07-20       Impact factor: 5.650

6.  The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform.

Authors:  F Chesnel; P Hascoet; J P Gagné; A Couturier; F Jouan; G G Poirier; C Le Goff; C Vigneau; Y Danger; F Verite; X Le Goff; Y Arlot-Bonnemains
Journal:  Br J Cancer       Date:  2015-06-02       Impact factor: 7.640

7.  The pVHL172 isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13.

Authors:  Pauline Hascoet; Franck Chesnel; Florence Jouan; Cathy Le Goff; Anne Couturier; Eric Darrigrand; Fabrice Mahe; Nathalie Rioux-Leclercq; Xavier Le Goff; Yannick Arlot-Bonnemains
Journal:  Oncotarget       Date:  2017-06-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.